4 ms·
That is probably the best approach: start manufacturing at scale as soon as the risk profile of a vaccine candidate offers a minimum of confidence for it to be
by Slartie 7y ago
That is probably the best approach: start manufacturing at scale as soon as the risk profile of a vaccine candidate offers a minimum of confidence for it to be working. And doing that with as many companies in the field as possible in parallel to increase probabilities of success.
As a retail investor living in Germany, this confirms my decision to put a little bit of money into Moderna stock. I would have done the same with CureVac, but they aren't listed at any stock exchange unfortunately.
- DrAwdeOccarim 7y agoBioNTech is also public (BNTX), so you should add some there too. But maybe wait for them to come back to Earth (up ~50% premarket from announcements!)
- Slartie 7y agoThanks for the tip, will keep an eye on them. Though I wonder why they shot up 50-60% while Moderna keeps trading normally. It does appear from the outside as if both of them were comparable from a liquidity standpoint and also with regard to their progress towards a working vaccine.
- DrAwdeOccarim 7y agoThey announced a collaboration with a Chinese company to start trials in April. So that news is the catalyst for the move. I am surprised Moderna isn't moving higher on news that they actually dosed, you know, a real live person. shrug the market seems to enjoy hating on Moderna. Oh well, they raised $500mil in January and are sitting on $1.9b so it doesnt' really matter what the stock does in the near/mid term.